5 Key Takeaways

• 1

  Eight trade associations from the EU and UK pharmaceutical industries urged for close cooperation on medicines post-Brexit.

• 2

  The letter warned that an unorderly withdrawal could disrupt supply chains and delay life-saving medicines at borders.

• 3

  The authors called for an implementation period after Brexit to allow companies to transition to a new regulatory framework.

• 4

  Concerns were raised about potential loss of capacity and expertise within the EMA if the UK leaves the European regulatory network.

• 5

  UK health secretary Jeremy Hunt acknowledged separate regulatory arrangements post-Brexit but expressed a desire to work closely with the EMA.